SNP-ACTH (Corticotropin porcine (synthetic) Gel)
Primary Membranous Nephropathy (PMN)
Phase 3Active
Key Facts
About Cerium Pharmaceuticals
Cerium Pharmaceuticals is a private, clinical-stage biotech founded in 2020 and based in Cambridge, Massachusetts, targeting rare kidney diseases. Its lead program, a synthetic ACTH gel, has received FDA Orphan Drug Designation and is poised to enter Phase 3 trials for Primary Membranous Nephropathy (PMN), an area with no approved therapies. The company is led by a seasoned team with deep experience in rare disease drug development and commercialization, and is backed by a $12 million Series B financing round to advance its clinical plans.
View full company profile